Marshall Wace, LLP Immunic, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Immunic, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 39,621 shares of IMUX stock, worth $61,412. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,621
Previous 49,529
20.0%
Holding current value
$61,412
Previous $65,000
33.85%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding IMUX
# of Institutions
64Shares Held
56.1MCall Options Held
4.7KPut Options Held
311K-
Avidity Partners Management LP Dallas, TX8.9MShares$13.8 Million0.49% of portfolio
-
Bvf Inc San Francisco, CA8.9MShares$13.8 Million0.3% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$11.3 Million0.82% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$11 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$8.67 Million0.01% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $47.4M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...